Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$104.97
-1.3%
$106.53
$72.21
$139.13
$5.24B0.46603,105 shs431,383 shs
Harrow, Inc. stock logo
HROW
Harrow
$37.24
+0.8%
$31.00
$20.85
$59.23
$1.36B0.41433,815 shs302,385 shs
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$70.93
-3.2%
$78.40
$69.12
$118.21
$5.07B0.121.09 million shs814,707 shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$36.24
-0.6%
$34.28
$27.66
$121.06
$4.70B1.191.46 million shs880,184 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+3.72%-4.46%+4.63%+0.90%+24.17%
Harrow, Inc. stock logo
HROW
Harrow
+2.33%+6.95%+19.19%+47.39%+50.94%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
+1.34%-1.48%-9.28%-29.26%-36.54%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
+2.07%-0.30%+9.65%+5.65%-56.57%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
4.7131 of 5 stars
4.51.00.04.52.54.20.6
Harrow, Inc. stock logo
HROW
Harrow
2.5905 of 5 stars
3.51.00.00.02.92.50.6
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
4.6915 of 5 stars
3.42.00.04.24.02.51.9
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
1.886 of 5 stars
3.61.00.00.02.61.70.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
3.06
Buy$172.3364.17% Upside
Harrow, Inc. stock logo
HROW
Harrow
3.00
Buy$63.8371.41% Upside
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
2.83
Moderate Buy$131.2084.97% Upside
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10
Buy$136.50276.66% Upside

Current Analyst Ratings Breakdown

Latest HROW, AXSM, LNTH, and PCVX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/16/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
7/11/2025
Harrow, Inc. stock logo
HROW
Harrow
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$76.00
7/3/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$190.00
6/23/2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$122.00 ➝ $109.00
6/12/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$193.00 ➝ $186.00
6/12/2025
Harrow, Inc. stock logo
HROW
Harrow
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$62.00
6/10/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$180.00
6/10/2025
Harrow, Inc. stock logo
HROW
Harrow
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
6/9/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$153.00 ➝ $150.00
6/3/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$185.00
5/22/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$180.00 ➝ $180.00
(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$385.69M13.40N/AN/A$1.18 per share88.96
Harrow, Inc. stock logo
HROW
Harrow
$199.61M6.85$0.14 per share264.08$1.95 per share19.10
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.53B3.20$6.95 per share10.20$15.65 per share4.53
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$26.52 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$287.22M-$5.77N/A37.22N/A-64.39%-272.80%-36.69%8/4/2025 (Estimated)
Harrow, Inc. stock logo
HROW
Harrow
-$17.48M-$0.56N/A93.10N/A-10.19%-25.01%-4.27%8/6/2025 (Estimated)
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$312.44M$3.5220.1511.24N/A16.55%36.99%20.55%7/30/2025 (Estimated)
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$463.93M-$3.99N/AN/AN/AN/A-17.12%-16.26%8/5/2025 (Estimated)

Latest HROW, AXSM, LNTH, and PCVX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Harrow, Inc. stock logo
HROW
Harrow
$0.01N/AN/AN/A$64.23 millionN/A
8/5/2025Q2 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.12N/AN/AN/AN/AN/A
8/4/2025Q2 2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$1.04N/AN/AN/A$140.02 millionN/A
7/30/2025Q2 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.65N/AN/AN/A$389.69 millionN/A
5/14/2025Q1 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.02-$1.04-$0.02-$1.04N/AN/A
5/8/2025Q1 2025
Harrow, Inc. stock logo
HROW
Harrow
$0.02-$0.38-$0.40-$0.50$57.00 million$47.83 million
5/7/2025Q1 2025
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
$1.64$1.53-$0.11$1.02$377.37 million$372.76 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Harrow, Inc. stock logo
HROW
Harrow
N/AN/AN/AN/AN/A
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
N/AN/AN/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
3.48
2.03
1.96
Harrow, Inc. stock logo
HROW
Harrow
2.01
0.91
0.85
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
0.49
5.74
5.46
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
17.70
17.70

Institutional Ownership

CompanyInstitutional Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Harrow, Inc. stock logo
HROW
Harrow
72.76%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
99.06%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%

Insider Ownership

CompanyInsider Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
22.30%
Harrow, Inc. stock logo
HROW
Harrow
15.16%
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
1.50%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38049.24 million38.26 millionOptionable
Harrow, Inc. stock logo
HROW
Harrow
18036.69 million31.12 millionOptionable
Lantheus Holdings, Inc. stock logo
LNTH
Lantheus
70069.19 million68.15 millionOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160129.00 million125.01 millionOptionable

Recent News About These Companies

Mizuho Maintains an Overweight Rating on Vaxcyte (PCVX)
Vaxcyte: Sentiment Is Pushing The Shares Down
Vaxcyte appoints new independent director

New MarketBeat Followers Over Time

Media Sentiment Over Time

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$104.97 -1.39 (-1.31%)
Closing price 04:00 PM Eastern
Extended Trading
$105.00 +0.03 (+0.03%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Harrow stock logo

Harrow NASDAQ:HROW

$37.24 +0.29 (+0.78%)
Closing price 04:00 PM Eastern
Extended Trading
$37.24 0.00 (0.00%)
As of 05:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Harrow, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

Lantheus stock logo

Lantheus NASDAQ:LNTH

$70.93 -2.38 (-3.25%)
Closing price 04:00 PM Eastern
Extended Trading
$72.10 +1.17 (+1.65%)
As of 07:22 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$36.24 -0.22 (-0.60%)
Closing price 04:00 PM Eastern
Extended Trading
$36.18 -0.05 (-0.15%)
As of 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.